These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 7870050

  • 21. Enhancement of the inhibitory action of APD on the transformation of osteoclast precursors into resorbing cells after dimethylation of the amino group.
    Boonekamp PM, Löwik CW, van der Wee-Pals LJ, van Wijk-van Lennep ML, Bijvoet OL.
    Bone Miner; 1987 Feb; 2(1):29-42. PubMed ID: 3504722
    [Abstract] [Full Text] [Related]

  • 22. Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
    Dunford JE, Kwaasi AA, Rogers MJ, Barnett BL, Ebetino FH, Russell RG, Oppermann U, Kavanagh KL.
    J Med Chem; 2008 Apr 10; 51(7):2187-95. PubMed ID: 18327899
    [Abstract] [Full Text] [Related]

  • 23. Mechanisms of action of the bisphosphonates.
    Fleisch H.
    Medicina (B Aires); 1997 Apr 10; 57 Suppl 1():65-75. PubMed ID: 9567358
    [Abstract] [Full Text] [Related]

  • 24. Determination of the microscopic equilibrium dissociation constants for risedronate and its analogues reveals two distinct roles for the nitrogen atom in nitrogen-containing bisphosphonate drugs.
    Hounslow AM, Carran J, Brown RJ, Rejman D, Blackburn GM, Watts DJ.
    J Med Chem; 2008 Jul 24; 51(14):4170-8. PubMed ID: 18590315
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity.
    Clézardin P, Ebetino FH, Fournier PG.
    Cancer Res; 2005 Jun 15; 65(12):4971-4. PubMed ID: 15958534
    [Abstract] [Full Text] [Related]

  • 27. Metabolism of halogenated bisphosphonates by the cellular slime mould Dictyostelium discoideum.
    Rogers MJ, Russell RG, Blackburn GM, Williamson MP, Watts DJ.
    Biochem Biophys Res Commun; 1992 Nov 30; 189(1):414-23. PubMed ID: 1333194
    [Abstract] [Full Text] [Related]

  • 28. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs.
    Plotkin LI, Manolagas SC, Bellido T.
    Bone; 2006 Sep 30; 39(3):443-52. PubMed ID: 16627025
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Pivaloyloxymethyl-modified isoprenoid bisphosphonates display enhanced inhibition of cellular geranylgeranylation.
    Wiemer AJ, Yu JS, Shull LW, Barney RJ, Wasko BM, Lamb KM, Hohl RJ, Wiemer DF.
    Bioorg Med Chem; 2008 Apr 01; 16(7):3652-60. PubMed ID: 18308574
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Bisphosphonates: mode of action and pharmacology.
    Russell RG.
    Pediatrics; 2007 Mar 01; 119 Suppl 2():S150-62. PubMed ID: 17332236
    [Abstract] [Full Text] [Related]

  • 33. Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo.
    Ghosh S, Chan JM, Lea CR, Meints GA, Lewis JC, Tovian ZS, Flessner RM, Loftus TC, Bruchhaus I, Kendrick H, Croft SL, Kemp RG, Kobayashi S, Nozaki T, Oldfield E.
    J Med Chem; 2004 Jan 01; 47(1):175-87. PubMed ID: 14695831
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Preclinical pharmacology of zoledronic acid.
    Green JR.
    Semin Oncol; 2002 Dec 01; 29(6 Suppl 21):3-11. PubMed ID: 12584689
    [Abstract] [Full Text] [Related]

  • 36. Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates.
    Sanders JM, Ghosh S, Chan JM, Meints G, Wang H, Raker AM, Song Y, Colantino A, Burzynska A, Kafarski P, Morita CT, Oldfield E.
    J Med Chem; 2004 Jan 15; 47(2):375-84. PubMed ID: 14711309
    [Abstract] [Full Text] [Related]

  • 37. Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group.
    Van Beek E, Löwik C, Que I, Papapoulos S.
    J Bone Miner Res; 1996 Oct 15; 11(10):1492-7. PubMed ID: 8889849
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Mechanism of osteoclast mediated bone resorption--rationale for the design of new therapeutics.
    Väänänen K.
    Adv Drug Deliv Rev; 2005 May 25; 57(7):959-71. PubMed ID: 15876398
    [Abstract] [Full Text] [Related]

  • 40. Osteoblast proliferation and maturation by bisphosphonates.
    Im GI, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS.
    Biomaterials; 2004 Aug 25; 25(18):4105-15. PubMed ID: 15046901
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.